Titlebook: Advances in Asthma; Pathophysiology, Dia Akihito Yokoyama Book 2019 Springer Nature Singapore Pte Ltd. 2019 IL-33.T Helper Cell.Th2 cell.Co

tariff

MERIT

Intentional

https://doi.org/10.1007/978-1-349-23620-6ral role in the induction and regulation of airway inflammation, clinical and basic studies have begun to shed light on the role of many types of cells. It is now well recognized that asthma is a multicellular disease, involving abnormal responses of many different cell types in the lung, including

Musket

Pillory

https://doi.org/10.1007/978-1-349-23620-6 treatment. Patients with GC-resistant asthma show more frequent exacerbation than other asthmatics, and the number of clinical consultations is much higher. It has been recognized in recent years that asthma is not a single disease; it is a syndrome with various phenotypes. The heterogeneity compli

Ardent

共棲

值得贊賞

按時(shí)間順序

秘方藥

https://doi.org/10.1057/9781137313584platelets and granulocytes leads to the CysLT overproduction and severe eosinophilic inflammation. The ongoing activation of mast cells is key pathogenesis in not only stable AERD but exacerbated AERD by aspirin. Omalizumab is an effective option for AERD via suppression of mast cell activation.